Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

Gut

Volumn 65, Issue 4, 2016, Pages 658-671

  Zhang, Tian Ying ^a   Yuan, Quan ^a   Zhao, Jing Hua ^a   Zhang, Ya Li ^a,e   Yuan, Lun Zhi ^a   Lan, Ying ^a   Lo, Yu Chieh ^c   Sun, Cheng Pu ^c   Wu, Chang Ru ^d   Zhang, Jun Fang ^a   Zhang, Ying ^a   Cao, Jia Li ^a   Guo, Xue Ran ^a   Liu, Xuan ^a   Mo, Xiao Bing ^b   Luo, Wen Xin ^a   Cheng, Tong ^a   Chen, Yi Xin ^a   Tao, Mi Hua ^c   Shih, James W K ^a   Zhao, Qin Jian ^a   Zhang, Jun ^a   Chen, Pei Jer ^d   Yuan, Y Adam ^a,b   Xia, Ning Shao ^a   more..

^a XIAMEN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Xiamen Blood Service   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; EPITOPE; FC RECEPTOR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 129G1; MONOCLONAL ANTIBODY 16G12; MONOCLONAL ANTIBODY 22F10; MONOCLONAL ANTIBODY 2B2; MONOCLONAL ANTIBODY 42B6; MONOCLONAL ANTIBODY 4D11; MONOCLONAL ANTIBODY 7H11; MONOCLONAL ANTIBODY A13A2; MONOCLONAL ANTIBODY A2C1; MONOCLONAL ANTIBODY E6F6; MONOCLONAL ANTIBODY E7G11; MONOCLONAL ANTIBODY G12F5; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS B; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LIVER CELL; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS PARTICLE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PROCEDURES; TRANSGENIC MOUSE; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DNA, VIRAL; EPITOPES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; PHAGOCYTOSIS; VIRUS REPLICATION;

EID: 84962045286     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308964     Document Type: Article

References (33)

1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
2. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
4. Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217.
5. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007;25:1421-34.
6. Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100-4.
7. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013;503:224-8.
8. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013;503:277-80.
9. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012;492:118-22.
10. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
11. Huang CH, Yuan Q, Chen PJ, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol 2012;57:720-9.
12. Yuan Q, Ge S, Xiong J, et al. A novel immunoassay for PreS1 and/or core-related antigens for detection of HBsAg variants. J Virol Methods 2010;168:108-13.
13. Wu MH, Ma WL, Hsu CL, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2010;2:32ra5.
14. Bissig KD, Le TT, Woods NB, et al. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007;104:20507-11.
15. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice. Nat Biotechnol 2007;25:903-10.
16. Huang LR, Wu HL, Chen PJ, et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 2006;103:17862-7.
17. Zeng Z, Kong X, Li F, et al. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier. J Immunol 2013;191:4184-93.
18. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001;276:6591-604.
19. Chen YC, Delbrook K, Dealwis C, et al. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci USA 1996;93:1997-2001.
20. Pacheco P, White D, Sulchek T. Effects of microparticle size and Fc density on macrophage phagocytosis. PLoS ONE 2013;8:e60989.
21. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006;103:4930-4.
22. Flannagan RS, Jaumouille V, Grinstein S. The cell biology of phagocytosis. Annu Rev Pathol 2012;7:61-98.
23. DiLillo DJ, Tan GS, Palese P, et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014;20:143-51.
24. Chung KM, Thompson BS, Fremont DH, et al. Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 2007;81:9551-5.
25. Huber VC, Lynch JM, Bucher DJ, et al. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001;166:7381-8.
26. Chen SH, Wu HL, Kao JH, et al. Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. PLoS ONE 2012;7:e36984.
27. Tan AT, Koh S, Goh V, et al. Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J Gastroenterol Hepatol 2008;23:833-43.
28. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol 2010;58:258-66.
29. Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002;195:1089-101.
30. Eren R, Ilan E, Nussbaum O, et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 2000;32:588-96.
31. Neumann AU, Phillips S, Levine I, et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 2010;52:875-85.
32. Jaoude GA, Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 2005;79:10460-6.
33. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.